Kentucky House Committee Approves Medical Cannabis Legislation
HB 136 will now proceed to the House floor for a vote
Frankfort, KY - February 12, 2020 (Investorideas.com Newswire) On Wednesday, the House Judiciary Committee voted in favor (17-1) of a bill that would legalize medical cannabis for patients with debilitating medical conditions in Kentucky. HB 136 will now head to the House of Representatives for a full vote.
The sponsor of HB 136, Rep. Jason Nemes (R-Louisville), filed similar legislation in 2019 that was approved by the House Judiciary Committee in a 16-1 vote, but the House adjourned without taking action. Fifty-one of the state's 100 representatives are listed as sponsors of HB 136.
A 2019 Kentucky Health Issues Poll showed that nine out of 10 Kentucky residents support legalizing cannabis for medical use. If enacted into law, Kentucky will join the 33 states (and Washington, D.C.) that have passed medical cannabis laws.
Gov. Andy Beshear was elected in November after supporting medical cannabis legislation on the campaign trail.
Statement from Matt Simon, legislative analyst at the Marijuana Policy Project:
"Kentuckians have been waiting far too long for safe, legal access to cannabis for medical use. Patients and doctors in other states have learned through experience that cannabis is beneficial as an alternative to opioids and other prescription drugs. Passing HB 136 is a moral imperative for Kentuckians who are suffering with debilitating medical conditions. Patients are very grateful to Rep. Nemes for his leadership and to the committee for moving this important bill forward."
The Marijuana Policy Project is the nation's largest marijuana policy organization. It has been a leading advocate for federal marijuana policy reforms since its founding in 1995, and it has played a leading role in most major state-level reforms that have occurred over the past two decades. For more information, visit https://www.mpp.org.
Today's top news story in defense and security at Investorideas.com:
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com